Celltrion Healthcare’s new subcutaneous (SC) formulation of its CT-P13 biosimilar infliximab has shown positive results for the treatment of rheumatoid arthritis (RA) compared to the intravenous version, according to the firm’s latest data.
At this year’s European Congress of Rheumatology, EULAR, the South Korean firm presented a two-part study investigating the pharmacokinetics, efficacy...






